Published in Ann Intern Med on July 01, 1989
Pulmonary vasculitis. Proc Am Thorac Soc (2006) 2.54
ANCA and associated diseases: immunodiagnostic and pathogenetic aspects. Clin Exp Immunol (1993) 2.44
Autoantibodies developing to myeloperoxidase and proteinase 3 in systemic vasculitis stimulate neutrophil cytotoxicity toward cultured endothelial cells. Am J Pathol (1992) 2.19
Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum (2012) 2.17
IgA and IgG antineutrophil cytoplasmic antibody engagement of Fc receptor genetic variants influences granulomatosis with polyangiitis. Proc Natl Acad Sci U S A (2011) 1.61
Clinical significance of antibodies against neutrophils in patients with inflammatory bowel disease and primary sclerosing cholangitis. Gut (1992) 1.60
Ultrastructural localization of proteinase 3, the target antigen of anti-cytoplasmic antibodies circulating in Wegener's granulomatosis. Am J Pathol (1990) 1.57
Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis--a meta-analysis. Rheumatology (Oxford) (2011) 1.49
ELISA is the superior method for detecting antineutrophil cytoplasmic antibodies in the diagnosis of systemic necrotising vasculitis. J Clin Pathol (1999) 1.46
Antineutrophil cytoplasmic autoantibodies interact with primary granule constituents on the surface of apoptotic neutrophils in the absence of neutrophil priming. J Exp Med (1996) 1.37
Anti-myeloperoxidase autoantibodies react with native but not denatured myeloperoxidase. Clin Exp Immunol (1992) 1.17
Serum markers of T cell activation in relapses of Wegener's granulomatosis. Clin Exp Immunol (1993) 1.13
pANCA represents a cross-reactivity to enteric bacterial antigens. J Clin Immunol (1998) 1.13
Neutrophil activation by anti-proteinase 3 antibodies in Wegener's granulomatosis: role of exogenous arachidonic acid and leukotriene B4 generation. J Exp Med (1996) 1.12
The ANCA test: its clinical relevance. Ann Rheum Dis (1990) 1.11
Occurrence of autoantibodies to human leucocyte elastase in Wegener's granulomatosis and other inflammatory disorders. Ann Rheum Dis (1993) 1.11
Rare diseases.3: Wegener's granulomatosis. Thorax (1999) 1.10
Staphylococcal superantigens and T cell expansions in Wegener's granulomatosis. Clin Exp Immunol (2003) 1.08
Relevance of classic anti-neutrophil cytoplasmic autoantibody (C-ANCA)-mediated inhibition of proteinase 3-alpha 1-antitrypsin complexation to disease activity in Wegener's granulomatosis. Clin Exp Immunol (1993) 1.04
Screening for anti-neutrophil cytoplasmic antibodies (ANCA): is indirect immunofluorescence the method of choice? Clin Exp Immunol (1995) 1.03
Activation of granulocytes by anti-neutrophil cytoplasmic antibodies (ANCA) in Wegener's granulomatosis: a predominant role for the IgG3 subclass of ANCA. Clin Exp Immunol (1995) 1.00
Antibodies to proteinase 3 increase adhesion of neutrophils to human endothelial cells. Clin Exp Immunol (1993) 0.99
Eye manifestations in patients with perinuclear antineutrophil cytoplasmic antibody-associated vasculitis: case series and literature review. Jpn J Ophthalmol (2007) 0.97
Proteolysis of classic anti-neutrophil cytoplasmic autoantibodies (C-ANCA) by neutrophil proteinase 3. Clin Exp Immunol (1995) 0.97
IgG subclass distribution and relative functional affinity of anti-myeloperoxidase antibodies in systemic vasculitis at presentation and during follow-up. Immunology (1991) 0.95
The clinical relevance of ANCA in vasculitis. Clin Exp Immunol (1993) 0.95
A proportion of proteinase 3 (PR3)-specific anti-neutrophil cytoplasmic antibodies (ANCA) only react with PR3 after cleavage of its N-terminal activation dipeptide. Clin Exp Immunol (1998) 0.94
Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin. Clin Exp Immunol (1995) 0.94
Proteinase 3, the target antigen of anticytoplasmic antibodies circulating in Wegener's granulomatosis. Immunolocalization in normal and pathologic tissues. Am J Pathol (1991) 0.94
Strawberry gums: a clinicopathological manifestation diagnostic of Wegener's granulomatosis? J Clin Pathol (1993) 0.93
Cytotoxic effects of antibodies to proteinase 3 (C-ANCA) on human endothelial cells. Clin Exp Immunol (1994) 0.93
Diverse target antigens recognized by circulating antibodies in anti-neutrophil cytoplasm antibody-associated renal vasculitides. Clin Exp Immunol (1990) 0.93
ANCA as a predictor of relapse: useful in patients with renal involvement but not in patients with nonrenal disease. J Am Soc Nephrol (2014) 0.93
Discrimination and variable impact of ANCA binding to different surface epitopes on proteinase 3, the Wegener's autoantigen. J Autoimmun (2010) 0.91
No association between neutrophil FcgammaRIIa allelic polymorphism and anti-neutrophil cytoplasmic antibody (ANCA)-positive systemic vasculitis. Clin Exp Immunol (1999) 0.91
Prevalence and characterization of perinuclear anti-neutrophil cytoplasmic antibodies (P-ANCA) directed against HMG1 and HMG2 in ulcerative colitis (UC). Clin Exp Immunol (1998) 0.91
A young lady presented with limited pulmonary Wegener's granulomatosis. Lung India (2008) 0.90
Wegener granulomatosis in childhood and adolescence. Eur J Pediatr (2004) 0.90
Pulmonary vasculitis. Thorax (1998) 0.90
Nuclear localization of the antigen detected by ulcerative colitis-associated perinuclear antineutrophil cytoplasmic antibodies. Am J Pathol (1995) 0.89
Relapsing polychondritis as a secondary phenomenon of primary systemic vasculitis. Ann Rheum Dis (1993) 0.89
Diagnosis of limited ophthalmic Wegener granulomatosis: distinctive pathologic features with ANCA test confirmation. Int Ophthalmol (2007) 0.89
Early experience with intravenous immunoglobulin treatment in Wegener's granulomatosis with ocular involvement. Graefes Arch Clin Exp Ophthalmol (1997) 0.88
Modern imaging of the tracheo-bronchial tree. World J Radiol (2010) 0.88
Wegener granulomatosis presenting with haemorragic stroke in a young adult. J Neurol (2005) 0.86
Immunization with anti-neutrophil cytoplasmic antibody (ANCA) induces the production of mouse ANCA and perivascular lymphocyte infiltration. Clin Exp Immunol (1995) 0.85
Simplified method of preparing neutrophil slides to examine antibodies to cytoplasmic antigens. J Clin Pathol (1990) 0.85
Wegener's granulomatosis: anti-proteinase 3 antibodies are potent inductors of human endothelial cell signaling and leakage response. J Exp Med (1998) 0.85
Salivary gland involvement as initial presentation of Wegener's disease. Postgrad Med J (1993) 0.84
Galactosylation and Sialylation Levels of IgG Predict Relapse in Patients With PR3-ANCA Associated Vasculitis. EBioMedicine (2017) 0.82
Opsonization of apoptotic neutrophils by anti-neutrophil cytoplasmic antibodies (ANCA) leads to enhanced uptake by macrophages and increased release of tumour necrosis factor-alpha (TNF-alpha). Clin Exp Immunol (2000) 0.82
Wegener's granulomatosis: a model of auto-antibodies in mucosal autoimmunity. Clin Immunol (2009) 0.81
Assessment of disease activity in systemic vasculitis. Postgrad Med J (1998) 0.80
Inflammatory cells and cellular activation in the lower respiratory tract in Churg-Strauss syndrome. Thorax (1999) 0.79
Human FcR polymorphism and disease. Curr Top Microbiol Immunol (2014) 0.79
A novel specificity of anticytoplasmic autoantibodies directed against eosinophil peroxidase. Clin Exp Immunol (1993) 0.79
[B lymphocyte differentiation in granulomatous tissues of the lung and the nasal mucosa in Wegener's granulomatosis: origin of anti-neutrophil cytoplasmic antibody formation?]. Z Rheumatol (2007) 0.78
Wegener's granulomatosis of the prostate gland. Rheumatol Int (2003) 0.77
Bilateral papillitis with anti-neutrophil cytoplasmic antibodies associated with coeliac disease. Postgrad Med J (1991) 0.77
IgA- and SIgA anti-PR3 antibodies in serum versus organ involvement and disease activity in PR3-ANCA-associated vasculitis. Clin Exp Immunol (2016) 0.77
Anti-neutrophil cytoplasmic antibodies target sequential functional proteinase 3 epitopes in the sera of patients with Wegener’s granulomatosis. Clin Exp Immunol (2010) 0.77
Respiratory diseases. Postgrad Med J (1990) 0.76
A local presentation of systemic disease. Postgrad Med J (1996) 0.75
Wegener's granulomatosis presenting as dilated cardiomyopathy. West J Med (1996) 0.75
Florid xanthelasmata (yellow lids) in orbital Wegener's granulomatosis. Br J Ophthalmol (1995) 0.75
[Wegener's granulomatosis and microscopic polyangiitis]. Z Rheumatol (2009) 0.75
Limited Wegener's Granulomatosis Presenting with an Isolated Abduction Deficit. Neuroophthalmology (2014) 0.75
Polyneuritis cranialis and C-ANCA: is it limited Wegener's granulomatosis? J R Soc Med (1993) 0.75
Serial functional affinity of autoantibodies in anti-glomerular basement membrane disease. Clin Exp Immunol (1994) 0.75
Pulmonary metastasis in a patient with simultaneous bladder cancer and relapsing granulomatosis with polyangiitis. Am J Case Rep (2015) 0.75
New perspectives in Wegener's granulomatosis. Thorax (1993) 0.75
[ANCA-associated vasculitides. Classifying the disease and its activity according to EULAR/EUVAS recommendations]. Z Rheumatol (2009) 0.75
Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum (1994) 14.16
2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum (2013) 11.18
Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. Kidney Int (1998) 4.31
Anti-neutrophil cytoplasm antibodies in Wegener's granulomatosis recognize an elastinolytic enzyme. J Exp Med (1990) 3.37
Study of Health In Pomerania (SHIP): a health examination survey in an east German region: objectives and design. Soz Praventivmed (2001) 3.17
A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum (2001) 3.15
An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum (2000) 3.06
Rituximab treatment of idiopathic membranous nephropathy. Kidney Int (2007) 2.85
Neurological involvement in Wegener's granulomatosis: an analysis of 324 consecutive patients at the Mayo Clinic. Ann Neurol (1993) 2.75
Standardized neurologic evaluations of 128 patients with Wegener granulomatosis. Arch Neurol (2001) 2.69
Allergic granulomatosis and angiitis (Churg-Strauss syndrome). Report and analysis of 30 cases. Mayo Clin Proc (1977) 2.62
Antineutrophil cytoplasmic antibodies. Arthritis Rheum (1998) 2.53
Ocular complications of Wegener's granulomatosis. Ophthalmology (1983) 2.47
Anticytoplasmic antibodies in Wegener's granulomatosis. Lancet (1986) 2.12
Autoantibodies against cytoplasmic structures of neutrophil granulocytes in Wegener's granulomatosis. Clin Exp Immunol (1987) 2.09
Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis (2007) 2.01
Improved differentiation between Churg-Strauss syndrome and Wegener's granulomatosis by an artificial neural network. Arthritis Rheum (2001) 2.00
Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford) (2002) 1.98
Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology (Oxford) (2007) 1.95
Clinical implications of the histopathologic diagnosis of pulmonary lymphomatoid granulomatosis. Mayo Clin Proc (1990) 1.89
The value of indirect immunofluorescence and solid phase techniques for ANCA detection. A report on the first phase of an international cooperative study on the standardization of ANCA assays. EEC/BCR Group for ANCA Assay Standardization. J Immunol Methods (1993) 1.86
Anti-neutrophil cytoplasmic antibodies engage and activate human neutrophils via Fc gamma RIIa. J Immunol (1994) 1.76
Antineutrophil cytoplasmic antibodies reacting with the pro form of proteinase 3 and disease activity in patients with Wegener's granulomatosis and microscopic polyangiitis. Arthritis Rheum (2001) 1.76
Wegener's granulomatosis: observations on treatment with antimicrobial agents. Mayo Clin Proc (1985) 1.75
Wegener's granulomatosis associated with vasculitis of the temporal artery: report of five cases. Mayo Clin Proc (1993) 1.75
Chronic nitrofurantoin pulmonary reaction. Report of 5 cases. N Engl J Med (1968) 1.67
Anticytoplasmic autoantibodies in the diagnosis and follow-up of Wegener's granulomatosis. Mayo Clin Proc (1989) 1.64
Neurologic manifestations of Churg-Strauss syndrome. Mayo Clin Proc (1995) 1.61
Activated neutrophils express proteinase 3 on their plasma membrane in vitro and in vivo. Clin Exp Immunol (1994) 1.61
Cyclosporin for acute dermatomyositis. Lancet (1984) 1.61
A new type of perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) in active ulcerative colitis but not in Crohn's disease. Immunobiology (1990) 1.60
Recurrence of ANCA-associated vasculitis following renal transplantation in the modern era of immunosupression. Kidney Int (2007) 1.60
Cytokine profiles in Wegener's granulomatosis: predominance of type 1 (Th1) in the granulomatous inflammation. Arthritis Rheum (1999) 1.59
Subacute bacterial endocarditis with positive cytoplasmic antineutrophil cytoplasmic antibodies and anti-proteinase 3 antibodies. Arthritis Rheum (2000) 1.57
Ultrastructural localization of proteinase 3, the target antigen of anti-cytoplasmic antibodies circulating in Wegener's granulomatosis. Am J Pathol (1990) 1.57
Giant cell arteritis is more prevalent in urban than in rural populations: results of an epidemiological study of primary systemic vasculitides in Germany. Rheumatology (Oxford) (2000) 1.52
Development and validation of a disease extent index for Wegener's granulomatosis. Clin Nephrol (2001) 1.51
Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis. Arthritis Rheum (1994) 1.51
Colchicine versus prednisone as treatment of usual interstitial pneumonia. Mayo Clin Proc (1997) 1.45
Elevated serum levels of soluble interleukin-2 receptor in patients with Wegener's granulomatosis. Association with disease activity. Arthritis Rheum (1992) 1.44
Wegener's granulomatosis associated with renal cell carcinoma. Arthritis Rheum (1999) 1.42
Head and neck manifestations of Wegener's granulomatosis. Rhinology (2006) 1.41
Costimulatory molecules in Wegener's granulomatosis (WG): lack of expression of CD28 and preferential up-regulation of its ligands B7-1 (CD80) and B7-2 (CD86) on T cells. Clin Exp Immunol (1998) 1.39
[The risk profile of low-dose methotrexate in the therapy of chronic polyarthritis]. Dtsch Med Wochenschr (1992) 1.39
Lack of association between antiphospholipid antibodies and thrombocytopenia in patients with Wegener's granulomatosis. Semin Arthritis Rheum (2001) 1.38
What became of the rotating internship? Mayo Clin Proc (1981) 1.38
Treatment of Wegener's granulomatosis: the view from two non-nephrologists. Nephrol Dial Transplant (1994) 1.38
Lesions of the respiratory tract associated with the finding of anti-neutrophil cytoplasmic autoantibodies with a perinuclear staining pattern. Mayo Clin Proc (1994) 1.37
The leucotriene receptor antagonist montelukast and the risk of Churg-Strauss syndrome: a case-crossover study. Thorax (2008) 1.35
TAP deficiency syndrome. Clin Exp Immunol (2000) 1.35
Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis (2005) 1.33
Detection and quantitation of anti-neutrophil cytoplasm antibodies in Wegener's granulomatosis by ELISA using affinity-purified antigen. J Immunol Methods (1988) 1.33
Integrin and Arg-Gly-Asp dependence of cell adhesion to the native and unfolded triple helix of collagen type VI. Exp Cell Res (1993) 1.33
The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement. Rheumatology (Oxford) (2008) 1.32
Cryoglobulinemic vasculitis. Arthritis Rheum (1999) 1.31
Wegener's autoantigen decoded. Nature (1990) 1.31
[Antineutrophilic cytoplasmic antibodies (ANCA) in inflammatory rheumatic diseases: immunodiagnostic and immunopathogenetic aspects]. Z Rheumatol (1995) 1.31
Serum angiotensin-converting enzyme activity in evaluating the clinical course of sarcoidosis. Ann Intern Med (1980) 1.27
Lung toxicity associated with cyclophosphamide use. Two distinct patterns. Am J Respir Crit Care Med (1996) 1.27
Functional prothrombinase complex assembly on isolated monocytes and lymphocytes. J Biol Chem (1983) 1.25
Racial difference in cardiac sarcoidosis incidence observed at autopsy. Sarcoidosis (1994) 1.24
CD28 negative T cells are enriched in granulomatous lesions of the respiratory tract in Wegener's granulomatosis. Thorax (2001) 1.24
Cutaneous Wegener's granulomatosis: clinical, histopathologic, and immunopathologic features of thirty patients. J Am Acad Dermatol (1994) 1.23
Cocaine-induced midline destructive lesions: clinical, radiographic, histopathologic, and serologic features and their differentiation from Wegener granulomatosis. Medicine (Baltimore) (2001) 1.22
Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis. A randomized prospective study. Members of the Lung Study Group. Am J Respir Crit Care Med (1998) 1.20
Blount disease (tibia vara): another skeletal disorder associated with childhood obesity. J Pediatr (1982) 1.19
Correlation between HRCT findings, pulmonary function tests and bronchoalveolar lavage cytology in interstitial lung disease associated with rheumatoid arthritis. Eur Radiol (2003) 1.19
Human endothelial cells express proteinase 3, the target antigen of anticytoplasmic antibodies in Wegener's granulomatosis. Blood (1993) 1.18
Immunohistochemical localization of transforming growth factor-beta 1 in the nonnecrotizing granulomas of pulmonary sarcoidosis. Am J Respir Crit Care Med (1994) 1.18
Transforming growth factor-beta and suppression of humoral immune responses in HIV infection. J Clin Invest (1991) 1.18
Efficacy of transbronchial biopsy in pulmonary vaculitides. Eur Respir J (1997) 1.18
Severe CNS manifestations as the clinical hallmark in generalized Wegener's granulomatosis consistently negative for antineutrophil cytoplasmic antibodies (ANCA). A report of 3 cases and a review of the literature. Clin Exp Rheumatol (2001) 1.17
Candida albicans stimulates arachidonic acid liberation from alveolar macrophages through alpha-mannan and beta-glucan cell wall components. Infect Immun (1994) 1.16
Equilibrium measurements of the interactions of guanine nucleotides with Escherichia coli elongation factor G and the ribosome. Biochemistry (1976) 1.16
Promoter polymorphism rs3087456 in the MHC class II transactivator gene is not associated with susceptibility for selected autoimmune diseases in German patient groups. Int J Immunogenet (2006) 1.16
Differences between human proteinase 3 and neutrophil elastase and their murine homologues are relevant for murine model experiments. FEBS Lett (2005) 1.15
Two-dimensional echocardiographic findings in systemic sarcoidosis. Am J Cardiol (1989) 1.15
Tracheobronchial involvement in Wegener's granulomatosis. Am J Respir Crit Care Med (1995) 1.13
Anti-neutrophil cytoplasmic antibodies (ANCA) directed against bactericidal/permeability increasing protein (BPI): a new seromarker for inflammatory bowel disease and associated disorders. Clin Exp Immunol (1996) 1.13
Localized Wegener's granulomatosis: predominance of CD26 and IFN-gamma expression. J Pathol (2000) 1.13
Cyclophosphamide-induced bladder toxicity in Wegener's granulomatosis. Arthritis Rheum (1988) 1.13
Neutrophil activation by anti-proteinase 3 antibodies in Wegener's granulomatosis: role of exogenous arachidonic acid and leukotriene B4 generation. J Exp Med (1996) 1.12
Existence of the Frank-Starling mechanism in the failing human heart. Investigations on the organ, tissue, and sarcomere levels. Circulation (1996) 1.12
Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. Ann Rheum Dis (2008) 1.12
Prevalence and spectrum of rheumatic diseases associated with proteinase 3-antineutrophil cytoplasmic antibodies (ANCA) and myeloperoxidase-ANCA. Rheumatology (Oxford) (2001) 1.12
Antineutrophil cytoplasmic antibodies in systemic lupus erythematosus. Prevalence, specificities, and clinical significance. Arthritis Rheum (1995) 1.11
Pulmonary and extrapulmonary sarcoidosis in relation to circulating immune complexes: a quantification of immune complexes by two radioimmunoassays. Am Rev Respir Dis (1977) 1.10
Successful treatment of refractory anterior scleritis in primary Sjogren's syndrome with rituximab. Ann Rheum Dis (2005) 1.10
Polymorphic reticulosis, lymphomatoid granulomatosis. Two diseases or one? Mayo Clin Proc (1978) 1.10
The present status of treatment of pulmonary sarcoidosis: a house divided. Chest (1977) 1.10